Transcatheter Pulmonary Valve Treatment
In 2007, interventional cardiologists at NewYork-Presbyterian Morgan Stanley Children’s Hospital performed the first catheterization-based pulmonary valve replacement in the state of New York, as part of the first FDA trial in the United States involving transcatheter valve placement for congenital heart disease (CHD). Until that time, replacing a faulty pulmonary valve could be done only with open-heart surgery.
We have the largest transcatheter valve program for congenital heart disease in New York State
This transcatheter valve procedure has evolved into a viable alternative to surgical valve replacement, allowing us to replace the patient’s pulmonary valve by passing the device (valve with stent frame) within a small-diameter tube (called a sheath), through a vein in the leg, and up into the heart. The goal of this procedure is to replace the pulmonary valve nonsurgically, and decrease the number of open-heart surgeries a patient with congenital heart disease may need over a lifetime.
Over the last decade, our interventional cardiologists have performed more than 140 of these procedures in children and adults with CHD. NewYork-Presbyterian is the primary referral hospital for transcatheter pulmonary valve replacement in the greater New York City area, with procedures being performed on both the Columbia and Weill Cornell campuses.©New York-Presbyterian Hospital and its interventional cardiology team are internationally recognized for their expertise and as a center of excellence for this procedure.
Pre-transcatheter Pulmonary Valve Replacement
Post-transcatheter Pulmonary Valve Replacement
Total Transcatheter Pulmonary Valve Replacement Volume = 48 2013-2016
Our interventional cardiologists currently perform more than 20 transcatheter pulmonary valve replacements each year.